|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
65,769,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Nuvalent is a biopharmaceutical company. Co.'s product candidate, NVL-520, is a ROS proto-oncogene 1 (ROS1)-selective inhibitor designed with the aim to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of available ROS1 tyrosine kinase inhibitors. Co.'s another product candidate, NVL-655, is a brain-penetrant anaplastic lymphoma kinase (ALK)-selective inhibitor, designed with the aim to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first-, second-, and third-generation ALK inhibitors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
799,253 |
Total Buy Value |
$0 |
$0 |
$0 |
$26,774,976 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
2 |
Total Shares Sold |
1,255,333 |
1,496,679 |
1,700,539 |
1,985,239 |
Total Sell Value |
$90,498,964 |
$108,598,573 |
$118,726,529 |
$126,687,112 |
Total People Sold |
5 |
7 |
8 |
8 |
Total Sell Transactions |
18 |
27 |
48 |
84 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Turner Christopher Durant |
Chief Medical Officer |
|
2022-05-17 |
4 |
OE |
$6.89 |
$99,995 |
D/D |
14,513 |
14,513 |
|
- |
|
Noci Darlene |
See Remarks |
|
2022-02-15 |
4 |
AS |
$17.17 |
$72,114 |
D/D |
(4,200) |
0 |
|
- |
|
Noci Darlene |
See Remarks |
|
2022-02-15 |
4 |
OE |
$1.08 |
$4,536 |
D/D |
4,200 |
4,200 |
|
- |
|
Conley Emily |
Director |
|
2022-02-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8 |
|
- |
|
Deerfield Private Design Fund Iv, L.p. |
Director by Deputization |
|
2021-08-02 |
4 |
A |
$0.00 |
$0 |
I/I |
18,783,622 |
9,670,511 |
|
- |
|
Hack Andrew A. F. |
Director |
|
2021-08-02 |
4 |
B |
$17.00 |
$12,495,000 |
I/I |
735,000 |
3,428,014 |
2.1 |
- |
|
Hack Andrew A. F. |
Director |
|
2021-08-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,693,014 |
2,693,014 |
|
- |
|
Wellington Biomedical Innovation Master Investors |
10% Owner |
|
2021-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
897,671 |
897,671 |
|
- |
|
158 Records found
|
|
Page 7 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|